Aliskiren hemifumarate is the generic name for Tekturna, a medication used to treat high blood pressure [1].
When Does Aliskiren Hemifumarate Patent Protection End?
The primary patents protecting aliskiren hemifumarate, including those related to its composition of matter and methods of use, are nearing or have passed their expiration dates. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals. Specific patent expiration dates can vary based on jurisdiction and any granted extensions [2]. For instance, patents that were filed earlier and received extensions due to regulatory review delays might have later expiration dates [2].
How Does Aliskiren Hemifumarate Work?
Aliskiren hemifumarate functions as a direct renin inhibitor [1]. Renin is an enzyme produced by the kidneys that initiates the renin-angiotensin-aldosterone system (RAAS), a cascade that leads to the production of angiotensin II. Angiotensin II is a potent vasoconstrictor, meaning it narrows blood vessels, and also stimulates the release of aldosterone, which causes the body to retain sodium and water, both of which increase blood pressure [1]. By directly inhibiting renin, aliskiren hemifumarate prevents the initial step in this cascade, thereby reducing angiotensin II levels, leading to vasodilation and decreased blood pressure [1].
What Are the Risks and Side Effects of Aliskiren Hemifumarate?
Common side effects of aliskiren hemifumarate can include diarrhea, cough, and rash [1]. More serious risks are associated with its use in specific patient populations. It should not be used in patients with diabetes who are also taking an ACE inhibitor or an angiotensin II receptor blocker (ARB) due to an increased risk of kidney problems, low blood pressure, and high potassium levels [1]. Pregnant women should also avoid aliskiren hemifumarate as it can cause injury or death to the developing fetus [1].
Can Generic Aliskiren Hemifumarate Be Available?
The availability of generic versions of aliskiren hemifumarate depends on the expiration of its patent and any market exclusivity periods granted by regulatory bodies. Once these protections expire and if the U.S. Food and Drug Administration (FDA) approves generic applications, bioequivalent versions of the drug can become available. DrugPatentWatch.com monitors these developments [2].
Who Makes Aliskiren Hemifumarate?
The brand-name aliskiren hemifumarate, Tekturna, was originally developed and marketed by Novartis [1]. As patents expire, other pharmaceutical companies may seek to manufacture and market generic versions.
How Does Aliskiren Hemifumarate Compare to Other Blood Pressure Medications?
Aliskiren hemifumarate is unique among antihypertensive medications because it targets the very first step of the RAAS pathway by directly inhibiting renin [1]. Many other common blood pressure medications work further down this cascade. For example, ACE inhibitors block the conversion of angiotensin I to angiotensin II, while ARBs block the action of angiotensin II on its receptors [1]. Diuretics work by increasing salt and water excretion, reducing blood volume. Beta-blockers reduce heart rate and the force of heart contractions. Calcium channel blockers relax blood vessels. The choice of medication depends on individual patient factors and medical history [1].
What Happens if Aliskiren Hemifumarate is Used in Combination Therapy?
Aliskiren hemifumarate can be used in combination with other blood pressure medications, such as thiazide diuretics or calcium channel blockers, to achieve better blood pressure control [1]. However, its combination with ACE inhibitors or ARBs in patients with diabetes is contraindicated due to increased risks [1].
What are the Current Clinical Trial Data for Aliskiren Hemifumarate?
Clinical trials have demonstrated that aliskiren hemifumarate is effective in lowering blood pressure when used as monotherapy or in combination with other antihypertensive agents [1]. Studies have investigated its efficacy and safety profile across different patient demographics and co-existing conditions.
Are There Any Alternatives to Aliskiren Hemifumarate for High Blood Pressure?
Yes, there are numerous alternative drug classes for managing high blood pressure, including ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics [1]. The selection of an alternative would depend on the patient's specific medical needs, tolerance to side effects, and other health conditions.
Sources:
[1] https://www.drugs.com/tekturna.html
[2] https://drugpatentwatch.com